JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $87,992,000 | -4.6% | 1,925,000 | -6.3% | 2.48% | -2.9% |
| Q3 2017 | $92,187,000 | +41.2% | 2,055,000 | -5.9% | 2.55% | +27.9% |
| Q2 2017 | $65,310,000 | +34.7% | 2,185,000 | 0.0% | 2.00% | +25.9% |
| Q1 2017 | $48,485,000 | +37.5% | 2,185,000 | +16.8% | 1.59% | +21.4% |
| Q4 2016 | $35,250,000 | -16.4% | 1,870,000 | +33.1% | 1.31% | -11.9% |
| Q3 2016 | $42,164,000 | -15.9% | 1,405,000 | +7.7% | 1.48% | -25.2% |
| Q2 2016 | $50,164,000 | +0.9% | 1,305,000 | 0.0% | 1.98% | +0.2% |
| Q1 2016 | $49,707,000 | -13.4% | 1,305,000 | 0.0% | 1.98% | +22.3% |
| Q4 2015 | $57,381,000 | +8.1% | 1,305,000 | 0.0% | 1.62% | -4.0% |
| Q3 2015 | $53,100,000 | +121.3% | 1,305,000 | +190.0% | 1.68% | +158.7% |
| Q2 2015 | $23,999,000 | – | 450,000 | – | 0.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |